Search research articles
Contact Us
Filters
Showing results (101-110 of 136) with videos related to
Page
of 14
Sort By:
Clinical and Experimental Rheumatology
|
April 27, 2019
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)
Thomas Dörner, Hendrik Schulze-Koops, Gerd-Rüdiger Burmester, et al.
Immunotherapy
|
May 12, 2025
Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary
Marc Schmalzing, Herbert Kellner, Ayman Askari, et al.
Vaccine
|
January 19, 2024
Immunogenicity of tick-borne-encephalitis-virus-(TBEV)-vaccination and impact of age on humoral and cellular TBEV-specific immune responses in patients with rheumatoid arthritis
Christoph Rack, Giovanni Almanzar, Arne Schäfer, et al.
Rheumatology International
|
April 29, 2024
The exercise-app Axia for axial spondyloarthritis enhances the home-based exercise frequency in axial spondyloarthritis patients - A cross-sectional survey
Patrick-Pascal Strunz, Maxime Le Maire, Tobias Heusinger, et al.
Annals of the Rheumatic Diseases
|
March 13, 2026
An app-based nonpharmacological intervention improves patient-reported disease activity, functionality, and quality of life in patients with axial spondyloarthritis: a randomised controlled trial
Patrick-Pascal Strunz, Matthias Froehlich, Tobias Heusinger, et al.
Rheumatology International
|
April 15, 2025
Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database
Linus Maximilian Risser, Torsten Witte, Matthias Englbrecht, et al.
Zeitschrift Fur Rheumatologie
|
September 23, 2025
[Renewed increase in new Janus kinase inhibitor prescriptions : Analysis of the German RHADAR registry]
Patrick-Pascal Strunz, Linus Maximilian Risser, Matthias Englbrecht, et al.
Frontiers in Immunology
|
September 6, 2024
Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study
Patrick-Pascal Strunz, Linus Maximilian Risser, Matthias Englbrecht, et al.
Advances in Therapy
|
November 11, 2023
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study
Marc Schmalzing, Herbert Kellner, Ayman Askari, et al.
International Journal of Molecular Sciences
|
August 14, 2025
Influence of a Th17-Inducing Cytokine Milieu on Phenotypical and Functional Properties of Regulatory T Cells in Chronic Inflammatory Arthritis
Tobias Schwarz, Giovanni Almanzar, Marie Wulfheide, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 136) with videos related to
Sort By:
Page
of 14
Clinical and Experimental Rheumatology
|
April 27, 2019
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)
Thomas Dörner, Hendrik Schulze-Koops, Gerd-Rüdiger Burmester, et al.
Immunotherapy
|
May 12, 2025
Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary
Marc Schmalzing, Herbert Kellner, Ayman Askari, et al.
Vaccine
|
January 19, 2024
Immunogenicity of tick-borne-encephalitis-virus-(TBEV)-vaccination and impact of age on humoral and cellular TBEV-specific immune responses in patients with rheumatoid arthritis
Christoph Rack, Giovanni Almanzar, Arne Schäfer, et al.
Rheumatology International
|
April 29, 2024
The exercise-app Axia for axial spondyloarthritis enhances the home-based exercise frequency in axial spondyloarthritis patients - A cross-sectional survey
Patrick-Pascal Strunz, Maxime Le Maire, Tobias Heusinger, et al.
Annals of the Rheumatic Diseases
|
March 13, 2026
An app-based nonpharmacological intervention improves patient-reported disease activity, functionality, and quality of life in patients with axial spondyloarthritis: a randomised controlled trial
Patrick-Pascal Strunz, Matthias Froehlich, Tobias Heusinger, et al.
Rheumatology International
|
April 15, 2025
Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database
Linus Maximilian Risser, Torsten Witte, Matthias Englbrecht, et al.
Zeitschrift Fur Rheumatologie
|
September 23, 2025
[Renewed increase in new Janus kinase inhibitor prescriptions : Analysis of the German RHADAR registry]
Patrick-Pascal Strunz, Linus Maximilian Risser, Matthias Englbrecht, et al.
Frontiers in Immunology
|
September 6, 2024
Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study
Patrick-Pascal Strunz, Linus Maximilian Risser, Matthias Englbrecht, et al.
Advances in Therapy
|
November 11, 2023
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study
Marc Schmalzing, Herbert Kellner, Ayman Askari, et al.
International Journal of Molecular Sciences
|
August 14, 2025
Influence of a Th17-Inducing Cytokine Milieu on Phenotypical and Functional Properties of Regulatory T Cells in Chronic Inflammatory Arthritis
Tobias Schwarz, Giovanni Almanzar, Marie Wulfheide, et al.
Page
of 14